Search - tctmd.com

Displaying 1 - 20 of 153

Sort: Relevancy | Date

News Daily News

Side Effects of Statins Might Be Overstated: CTT Collaboration

Michael O'Riordan

February 12, 2026

News Daily News

Both Low-fat and Low-carb Diets Tied to Less Heart Disease

Michael O'Riordan

February 11, 2026

News Daily News

JACC Debuts Data Digest on CV Health in the United States

Caitlin E. Cox

January 12, 2026

News Daily News

Lp(a) Linked to 30-Year CVD Risk in Healthy Women

Michael O'Riordan

January 09, 2026

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

Better LDL Control After STEMI Means Less Neoatherosclerosis

Yael L. Maxwell

December 23, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Daily News

Risk Calculators Miss Many Patients Who Present With First MI

Michael O'Riordan

November 21, 2025

News Daily News

Risk Factors Present in Nearly All Patients Who Develop CVD

Michael O'Riordan

October 02, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Daily News

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Michael O'Riordan

September 18, 2025

News Daily News

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

Todd Neale

July 16, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

Todd Neale

June 06, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Michael O'Riordan

November 07, 2024

News Daily News

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Michael O'Riordan

October 14, 2024

News Daily News

COVID-19 Increases MACE Risk Nearly 3 Years Later: UK Biobank

Todd Neale

October 10, 2024

Advertisement

Side Effects of Statins Might Be Overstated: CTT Collaboration

Both Low-fat and Low-carb Diets Tied to Less Heart Disease

JACC Debuts Data Digest on CV Health in the United States

Lp(a) Linked to 30-Year CVD Risk in Healthy Women

Year in Review: Top Prevention Stories of 2025

Better LDL Control After STEMI Means Less Neoatherosclerosis

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Risk Calculators Miss Many Patients Who Present With First MI

Risk Factors Present in Nearly All Patients Who Develop CVD

CVD Still the Leading Cause of Death and Disease Globally

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

COVID-19 Increases MACE Risk Nearly 3 Years Later: UK Biobank

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content